Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avicanna Inc

Healthcare CA AVCN

0.11CAD
-0.015(12.00%)

Last update at 2026-06-05T18:52:00Z

Day Range

0.110.12
LowHigh

52 Week Range

0.140.31
LowHigh

Fundamentals

  • Previous Close 0.12
  • Market Cap18.87M
  • Volume173500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.24282M
  • Revenue TTM25.48M
  • Revenue Per Share TTM0.22
  • Gross Profit TTM 13.52M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.75920M -3.61800M -8.74300M -14.73529M -16.76077M
Minority interest - - - - -
Net income -2.84422M -3.61800M -8.74300M -17.21971M -16.77454M
Selling general administrative - 12.88M 11.89M 9.61M 12.53M
Selling and marketing expenses - 3.19M 2.16M 0.38M 0.35M
Gross profit 12.84M 12.90M 6.66M 1.12M 2.83M
Reconciled depreciation - 0.85M 0.78M 0.89M 0.89M
Ebit -2.71599M -3.28374M -8.13229M -10.57903M -10.83312M
Ebitda -1.97294M -2.43000M -7.35500M -9.69169M -9.93913M
Depreciation and amortization 0.74M 0.85M 0.78M 0.89M 0.89M
Non operating income net other - - - - -
Operating income -2.71599M -4.68000M -7.93300M -10.57903M -10.83312M
Other operating expenses 28.19M 30.14M 25.17M 14.46M 14.68M
Interest expense 0.05M 0.33M 0.61M 1.67M 0.74M
Tax provision - - - 0.00000M 0.01M
Interest income - 0.14M 0.58M 1.51M 1.82M
Net interest income - -0.33365M -0.61026M -1.67184M -0.73806M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.85748M 2.48M 0.01M
Total revenue 25.48M 25.46M 16.79M 4.05M 3.27M
Total operating expenses 15.56M 17.58M 15.04M 11.53M 14.25M
Cost of revenue 12.64M 12.56M 10.13M 2.93M 0.44M
Total other income expense net -0.04320M 1.06M -0.81000M -4.15626M -5.92766M
Discontinued operations - - - - -
Net income from continuing ops - -3.61768M -8.74300M -14.73529M -16.77454M
Net income applicable to common shares - -3.61768M -8.74300M -14.73529M -16.77454M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.24M 20.12M 21.97M 17.62M 22.30M
Intangible assets 0.63M 0.87M 1.19M 0.17M 0.30M
Earning assets - - - - -
Other current assets 0.22M - 0.47M 0.48M 0.90M
Total liab 9.86M 10.38M 14.00M 14.16M 15.39M
Total stockholder equity 2.84M 2.31M -0.11250M -0.38356M 1.15M
Deferred long term liab - - - - -
Other current liab 0.29M 0.30M 1.39M 3.84M 3.66M
Common stock 88.26M - 81.03M 74.89M 66.24M
Capital stock - 87.00M 81.03M 74.89M 66.24M
Retained earnings -105.23659M -102.09016M -98.71476M -90.82924M -77.40747M
Other liab - - - 2.35M 2.78M
Good will 0.33M 0.33M 0.33M - -
Other assets - - - - 0.00000M
Cash 0.28M 0.45M 0.48M 1.19M 0.03M
Cash and equivalents - - - - -
Total current liabilities 9.18M 9.27M 11.97M 11.41M 12.20M
Current deferred revenue 0.38M - - - -
Net debt -0.28063M - 1.33M 2.02M 1.63M
Short term debt - - 1.71M 2.81M 1.25M
Short long term debt - - 1.56M 2.66M 1.09M
Short long term debt total - - 1.80M 3.21M 1.66M
Other stockholder equity - - - 18.52M 16.47M
Property plant equipment - - - 10.39M 14.47M
Total current assets 7.90M 7.64M 8.46M 7.06M 7.35M
Long term investments - - - 0.00000M 0.18M
Net tangible assets - - - - 0.85M
Short term investments - - - - 0.00000M
Net receivables 3.55M 2.95M 2.97M 2.15M 2.34M
Long term debt - - - 0.18M 0.42M
Inventory 3.85M 3.97M 4.54M 3.24M 4.09M
Accounts payable 8.51M 7.77M 8.87M 4.75M 7.29M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 19.82M - 17.58M -2.97086M -4.15939M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 13.35M 12.48M 13.51M 10.55M 14.95M
Capital lease obligations - 0.11M 0.25M 0.37M 0.16M
Long term debt total - - - 0.40M 0.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.40257M -3.04722M 0.81M 1.25M
Change to liabilities - - - 0.00000M 0.81M
Total cashflows from investing activities -0.25584M -0.40257M -3.04722M 0.81M 0.76M
Net borrowings - -1.83354M -0.55292M - 0.88M
Total cash from financing activities 0.96M 3.41M 3.55M 9.90M 10.06M
Change to operating activities - - - - -0.01237M
Net income -2.84422M -3.61768M -8.74300M -14.73529M -16.77454M
Change in cash -0.16740M -0.02917M -0.71684M 1.16M -1.23573M
Begin period cash flow 0.45M 0.48M 1.19M 0.03M 1.27M
End period cash flow 0.28M 0.45M 0.48M 1.19M 0.03M
Total cash from operating activities -1.18124M -2.54711M -1.40422M -7.43537M -11.66302M
Issuance of capital stock - 4.80M 2.08M 9.08M 9.09M
Depreciation 0.74M 0.85M 0.78M 0.89M 0.89M
Other cashflows from investing activities - 0.00000M -0.49497M 0.88M 1.55M
Dividends paid - - - - -
Change to inventory -0.36471M 0.57M 1.16M 0.87M -2.15865M
Change to account receivables -0.98148M -0.26187M -1.24842M 0.37M -1.49918M
Sale purchase of stock - 4.93M 3.34M 9.08M 9.18M
Other cashflows from financing activities -0.03683M 0.44M 2.02M 2.23M 2.38M
Change to netincome - - - - 6.67M
Capital expenditures 0.26M 0.40M 0.56M 0.07M 0.79M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.05638M -0.79039M 4.36M 1.43M -2.44901M
Stock based compensation - 1.57M 1.94M 1.04M 1.31M
Other non cash items 0.98M -0.56516M 0.26M 3.94M 5.32M
Free cash flow -1.43711M -2.94968M -1.96178M -7.50215M -12.45226M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCN
Avicanna Inc		 -0.015 12.00% 0.11 - - 0.74 6.41 0.71 -4.2593
CURA
Curaleaf Holdings Inc.		 11.36 224.06% 16.43 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.09 1.16% 7.39 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 -0.03 0.77% 3.87 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 -0.39 5.40% 6.83 - 1000.00 1.28 0.53 1.08 -2.299

Reports Covered

Stock Research & News

View All

Profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol flower for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Avicanna Inc

480 University Avenue, Toronto, ON, Canada, M5G 1V2

Key Executives

Name Title Year Born
Mr. Aras Azadian B.Econ, Mba Co-Founder, CEO & Director NA
Dr. Frantz Le Devedec Exec. VP of R&D NA
Mr. Roland Alvarez SVP of Technical Operations NA
Ms. Ivana Maric Exec. VP of Marketing NA
Dr. Carlos Enrique Maldonado Muete SVP of Clinical Devel. NA
Ms. Caitlin Johnston Sr. VP of Strategic Partnerships & Patient Access NA
Mr. Phillip Cardella C.A., CPA Chief Financial Officer NA
Ms. Ivana Maric Executive Vice President of Marketing NA
Mr. Stephen Kim Chief Legal Officer & General Counsel of Avicanna USA Inc. NA
Dr. Karolina Urban Executive Vice President of Scientific & Medical Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.